Literature DB >> 10862157

Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis.

I Talmaciu1, L Varlotta, J Mortensen, D V Schidlow.   

Abstract

The number of patients with cystic fibrosis (CF) whose sputum culture has yielded Stenotrophomonas maltophilia has increased in the last 5 years at St. Christopher's Hospital for Children. We conducted a case-control study to determine risk factors for recovery of S. maltophilia in respiratory secretions from patients with CF. We reviewed the outpatient and inpatient records of patients colonized with S. maltophilia between 1993 and 1997, and of age-matched (at time of initial recovery of S. maltophilia) control patients with CF who had never had a positive sputum culture for S. maltophilia. Variables included age at time of CF diagnosis, gender, severity of CF (based on Shwachman-Kulczycki (S-K) scores and spirometry), frequency of hospitalizations, use of oral, intravenous, or inhaled antibiotics, and use of oral or inhaled corticosteroids in the 2 years prior to the first isolation of S. maltophilia from respiratory secretions. Statistical methods included stepwise logistic regression to determine risk factors for acquisition of S. maltophilia. During the study period, 58 patients with CF had a positive sputum or deep throat culture for S. maltophilia. The distribution of S. maltophilia acquisition by year increased from 7 patients in 1993 (incidence, 2.8%) to 16 in 1997 (incidence, 6.2%). Patients positive for S. maltophilia were found to have significantly worse growth parameters, S-K score, and spirometric values than S. maltophilia-negative CF controls (P < 0.05). Stepwise logistic regression demonstrated that treatment with long-term antibiotics (P = 0.0016) and number of days of intravenous antibiotic therapy (P = 0.035) were significant risk factors for S. maltophilia colonization in our group of CF patients. We conclude that patients with CF whose respiratory secretions yield S. maltophilia have an overall worse clinical status at the time of initial S. maltophilia isolation than noncolonized patients, and that preceding treatment with antibiotics may have predisposed them to the acquisition of this bacterium in their respiratory secretions. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10862157     DOI: 10.1002/1099-0496(200007)30:1<10::aid-ppul3>3.0.co;2-q

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  23 in total

1.  Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.

Authors:  Valerie J Waters; Marisa I Gómez; Grace Soong; Sunil Amin; Robert K Ernst; Alice Prince
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

2.  Identification and management of unusual pathogens in cystic fibrosis.

Authors:  J Stuart Elborn
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 4.  Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review.

Authors:  O Nyc; J Matejková
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

Review 5.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

6.  Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections.

Authors:  Melissa S McDaniel; Trenton Schoeb; W Edward Swords
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

Review 7.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 8.  Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.

Authors:  Christian Krauth; Noushin Jalilvand; Tobias Welte; Reinhard Busse
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 9.  Infection control in cystic fibrosis.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

10.  Low rates of Pseudomonas aeruginosa misidentification in isolates from cystic fibrosis patients.

Authors:  Timothy J Kidd; Kay A Ramsay; Honghua Hu; Peter T P Bye; Mark R Elkins; Keith Grimwood; Colin Harbour; Guy B Marks; Michael D Nissen; Philip J Robinson; Barbara R Rose; Theo P Sloots; Claire E Wainwright; Scott C Bell
Journal:  J Clin Microbiol       Date:  2009-03-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.